Product Name:2,4-Dichloropyrimidine

IUPAC Name:2,4-dichloropyrimidine

CAS:3934-20-1
Molecular Formula:C4H2Cl2N2
Purity:98%
Catalog Number:CM166462
Molecular Weight:148.97

Packing Unit Available Stock Price($) Quantity
CM166462-500g in stock ǵưǵ
CM166462-1000g in stock ʼnŢȎ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:3934-20-1
Molecular Formula:C4H2Cl2N2
Melting Point:-
Smiles Code:ClC1=NC(Cl)=NC=C1
Density:
Catalog Number:CM166462
Molecular Weight:148.97
Boiling Point:209.1°C at 760 mmHg
MDL No:MFCD00006061
Storage:Store in freezer, under -20°C.

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Momelotinib
GSK’s novel small molecule drug, Momelotinib (Ojjaara) has been approved by the U.S. FDA on September 15 for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia.
Myelofibrosis is a rare and fatal form of bone marrow cancer, often resulting in anemia, constitutional symptoms such as fatigue, night sweats, and bone pain, and splenomegaly. These key manifestations of myelofibrosis, including anaemia, have limited treatment options and causing over 30% patients discontinuing treatment.
Momelotinib fills a significant unmet medical need, and has a potential of being a standard-of-care treatment for newly diagnosed and previously treated patients with anaemia. Under a unique mechanism of action, Momelotinib, inhibits Janus kinase (JAK) 1, JAK2, and activin A receptor, type I (ACVR1) along three key signalling pathways. The phase III study has demonstrated clinical activity against anemia, constitutional symptoms, and splenomegaly.